Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | CNR1 | P21554 | 7/20 | 0.64 |
| ▸ | CNR2 | P34972 | 5/20 | 0.64 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.64 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.64 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.64 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.64 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.64 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.64 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.64 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.64 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.64 |
| ▸ | PSMA5 | P28066 | 2/20 | 0.64 |
| ▸ | PSMB4 | P28070 | 2/20 | 0.64 |
| ▸ | PSMB6 | P28072 | 2/20 | 0.64 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29714686 | 1.00 | ALDH1A1 (0.65) | ALDH1A1MAPTHPGDGLATHRB | |
| SCHEMBL4601891 | 0.93 | SOAT1 (0.69) | ALDH1A1MAPTHPGDGLATHRB | |
| SCHEMBL4601888 | 0.93 | SOAT1 (0.69) | ALDH1A1MAPTHPGDGLATHRB | |
| SCHEMBL29362769 | 0.85 | ALDH1A1 (0.80) | ALDH1A1MAPTHPGDGLATHRB | |
| SCHEMBL14246925 | 0.84 | EP300 (0.69) | SOAT2SOAT1 | |
| SCHEMBL3155514 | 0.84 | EP300 (0.69) | SOAT2SOAT1 | |
| SCHEMBL6920533 | 0.84 | EP300 (0.69) | SOAT2SOAT1 | |
| SCHEMBL1133527 | 0.84 | EP300 (0.69) | SOAT2SOAT1 | |
| SCHEMBL8446067 | 0.84 | EP300 (0.69) | SOAT2SOAT1 | |
| SCHEMBL1161259 | 0.84 | EP300 (0.69) | SOAT2SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339391-A1 | METHODS FOR EFFECTIVE MANAGEMENT OF PAIN | South Rampart Pharma, Inc. (US) | 2025-11-06 | — | — | US | claimed |
| WO-2018116250-A1 | METHOD FOR MODIFYING THE THERAPEUTIC EFFECTS OF DRUGS | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center (IL) | 2018-06-28 | — | — | WO | claimed |
| US-20260076921-A1 | Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis | PIKE THERAPEUTICS INC (CA) | 2026-03-19 | — | — | US | disclosed |
| US-20250339391-A1 | METHODS FOR EFFECTIVE MANAGEMENT OF PAIN | South Rampart Pharma, Inc. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250339391-A1 | METHODS FOR EFFECTIVE MANAGEMENT OF PAIN | South Rampart Pharma, Inc. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250312359-A1 | Transdermal Delivery of Tetrahydrocannabinol | Pike Therapeutics Inc. (CA) | 2025-10-09 | — | — | US | disclosed |
| US-20250248948-A1 | Transdermal and/or Topical, Pharmaceutical Formulations Comprising Cannabidiol and/or Tetrahydrocannabinol for the Treatment of Chronic Pain | PIKE THERAPEUTICS INC (CA) | 2025-08-07 | — | — | US | disclosed |
| US-20250186363-A1 | Pharmaceutical Compositions and Methods for Treating Parkinson's Disease | PIKE THERAPEUTICS INC (CA) | 2025-06-12 | — | — | US | disclosed |
| EP-4558135-A1 | CONTINUOUS DELIVERY SYSTEMS COMPRISING A CANNABINOID AND MEDICINAL USES THEREOF | Pike Therapeutics Inc. (CA) | 2025-05-28 | — | — | EP | disclosed |
| US-20250152601-A1 | Compositions and Methods for the Treatment of Sexual Dysfunctions | THE JONATHAN HURT LIVING TRUST (US) | 2025-05-15 | — | — | US | disclosed |
| CN-119923256-A | Continuous delivery system comprising cannabinoids and medical uses thereof | 长矛治疗股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20200179393-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING PAIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-11 | — | — | US | disclosed |
| US-20190329063-A1 | METHOD FOR MODIFYING THE THERAPEUTIC EFFECTS OF DRUGS | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center (IL) | 2019-10-31 | — | — | US | disclosed |
| WO-2018116250-A1 | METHOD FOR MODIFYING THE THERAPEUTIC EFFECTS OF DRUGS | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center (IL) | 2018-06-28 | — | — | WO | disclosed |
| US-20180000727-A1 | COMPOSITION AND METHODS TO IMPROVE STABILITY, DOSING, PHARMACODYNAMICS AND PRODUCT SHELF LIFE OF ENDOCANNABINOIDS, PHYTOCANNABINOIDS AND SYNTHETIC CANNABINOIDS DELIVERED BY NASAL INHAER | WILLINSKY MICHAEL (CA) | 2018-01-04 | — | — | US | disclosed |
| EP-3247402-A1 | COMPOSITION AND METHODS TO IMPROVE STABILITY, DOSING, PHARMACODYNAMICS AND PRODUCT SHELF LIFE OF ENDOCANNABINOIDS, PHYTOCANNABINOIDS AND SYNTHETIC CANNABINOIDS DELIVERED BY NASAL INHALER | Willinsky, Michael (CA) | 2017-11-29 | — | — | EP | disclosed |
| US-20170252469-A9 | Method for predicting autism spectrum disorders by cannabinoid and cannabinoid receptor expression | THE UNITED OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2017-09-07 | — | — | US | disclosed |
| US-20150374857-A1 | Method for predicting autism spectrum disorders by cannabinoid and cannabinoid receptor expression | SCHULTZ STEPHEN T (US) | 2015-12-31 | — | — | US | disclosed |
| US-20120225015-A1 | Method for predicting autism spectrum disorders by cannabinoid and cannabinoid receptor expression | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2012-09-06 | — | — | US | disclosed |
| US-20100261686-A1 | Pharmaceutical combination for the treatment of pain (acute or chronic), as powerful as a narcotic medication but non narcotic ,therefore very unlikely to create addiction | BENOIT JACQUES | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339391-A1 | METHODS FOR EFFECTIVE MANAGEMENT OF PAIN | SRP72, OPRL1, OPRK1 | ALDH1A1 2342/4885MAPT 3633/4885HPGD 1205/4885 |
| US-20250248948-A1 | Transdermal and/or Topical, Pharmaceutical Formulations Comprising Cannabidiol and/or Tetrahydrocannabinol for the Treatment of Chronic Pain | CNR2, CNR1, TRPV1 | ALDH1A1 4196/4885MAPT 475/4885HPGD 734/4885 |
| US-20260076921-A1 | Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis | SOST, CNR2, BHMT2 | ALDH1A1 4779/4885MAPT 60/4885HPGD 665/4885 |
| US-20250186363-A1 | Pharmaceutical Compositions and Methods for Treating Parkinson's Disease | PARK7, SNCA, COMT | ALDH1A1 1664/4885MAPT 50/4885HPGD 166/4885 |
| US-20200179393-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING PAIN | ACHE, MPO, MMP8 | ALDH1A1 1316/4885MAPT 2162/4885HPGD 695/4885 |
| US-20250312359-A1 | Transdermal Delivery of Tetrahydrocannabinol | CNR2, CNR1, OPRL1 | ALDH1A1 4654/4885MAPT 234/4885HPGD 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.